NEW YORK, Jan 4, 2026, 13:54 ET — Market closed
- Ironwood Pharmaceuticals shares surged 26.7% on Friday, ending at $4.27 after issuing 2026 financial guidance.
- The company forecast 2026 total revenue of $450 million to $475 million and adjusted EBITDA of more than $300 million.
- Investors are now waiting for Ironwood’s fourth-quarter update later this quarter for details on an apraglutide Phase 3 trial and any word on its strategic review.
Ironwood Pharmaceuticals shares jumped 26.7% on Friday to close at $4.27, outpacing the broader healthcare stock complex after the company laid out a sharply higher 2026 outlook tied to its Linzess constipation drug.
The move matters because Ironwood is trying to prove it can generate steady cash flow from a single commercial asset while it works through a strategic review and prepares a key late-stage study for its pipeline drug apraglutide.
It also lands at a sensitive moment for U.S. drug pricing, where headline list-price cuts do not always translate to lower “net” revenue after rebates and statutory discounts are applied. Ironwood is betting the math now swings in its favor. SEC
Ironwood said it expects 2026 Linzess U.S. net sales of $1.125 billion to $1.175 billion, with total revenue of $450 million to $475 million and adjusted EBITDA of more than $300 million. Adjusted EBITDA is a profit measure that strips out items such as interest, taxes and non-cash charges to show operating performance.
The company kept its 2025 targets intact, including Linzess U.S. net sales of $860 million to $890 million, total revenue of $290 million to $310 million and adjusted EBITDA above $135 million — setting up a step-change into 2026 if it executes.
Ironwood said it lowered Linzess’ list price effective Jan. 1 and expects higher net sales in 2026 because the cut reduces certain inflation-linked rebate obligations, including in Medicaid, even as prescription demand grows in the low single digits. Rebates are the back-end discounts manufacturers pay to insurers and government programs, which can rise when list prices climb.
The rally came on heavy volume, with the stock trading between $4.20 and $5.78 on Friday as investors reset expectations after the guidance.
“We are on track to initiate a confirmatory trial in the first half of 2026,” Chief Executive Tom McCourt said, adding the company expects to share the trial design in its fourth-quarter and full-year update later this quarter. SEC
But the upside case leans on assumptions that can move quickly — how payors respond to the new list price, whether rebate mechanics work as modeled, and whether Ironwood can stay within debt covenant limits while funding the apraglutide program and continuing its strategic review.
With U.S. markets reopening on Monday, traders will watch for any follow-on commentary from management and for the next earnings date; Wall Street calendars currently peg Ironwood’s next report for Feb. 26.
